De novo hepatocellular carcinoma in patients with cirrhosis due hepatitis C virus infection after treatment with direct antiviral agents

Ruíz, P.; Deiss, Louis P.; Buendía, Lidia; Erdozain, Inés López; Álvarez, Cristiam M.; Gutiérrez, Purificación; Pascual, Jordi Alberich; Baranda, A Sáinz de; Blanco, Sonia; Menéndez, Fernando; Calderón, A.; Esain, A.

doi:10.1016/s0168-8278(18)31315-1

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Forty‐four studies [ 13–57 ] with a total 35,739 patients and 107,548 person‐years follow‐up were included (Tables 1–3). Thirty‐six studies (29,444 patients, 91,049 person‐years follow‐up) had required data for calculating HCC incidence among patients with cirrhosis (Table 2), with cirrhosis defined by histopathology ( n = 7) or a combination of histopathology, liver stiffness measurement, imaging, or clinical features of cirrhosis ( n = 29) (Table ).…”

Section: Resultsmentioning

confidence: 99%

“…Forty‐four studies [ 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 ] with a total 35,739 patients and 107,548 person‐years follow‐up were included (Tables 1 , 2 , 3 ). Thirty‐six studies (29,444 patients, 91,049 person‐years follow‐up) had required data for calculating HCC incidence among patients with cirrhosis (Table 2 ), with cirrhosis defined by histopathology ( n = 7) or a combination of histopathology, liver stiffness measurement, imaging, or clinical feat...…”

Section: Resultsmentioning

confidence: 99%

“…Ruiz, 2018 (Spain) [42] Prospective, single-center a 226 ----Shiha, 2020 (Egypt) [43] Prospective, single-center 1,734 56 54% 0% 0%…”

Section: Analyses Among Studies Where All Patients Achieved Hcv With ...mentioning

confidence: 99%

See 2 more Smart Citations

HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta‐analysis

et al. 2022

View full text Add to dashboard Cite

Background and Aims HCV cure reduces but does not eliminate the risk of HCC. HCC surveillance is recommended in populations where the incidence exceeds 1.5% per year. In cirrhosis, HCC surveillance should continue after HCV cure, although it is uncertain if this should be indefinite. For patients with advanced fibrosis (F3), guidelines are inconsistent in their recommendations. We evaluated the incidence of HCC after HCV cure among patients with F3 fibrosis or cirrhosis. Approach and Results This systematic review and meta‐analysis identified 44 studies (107,548 person‐years of follow‐up) assessing the incidence of HCC after HCV cure among patients with F3 fibrosis or cirrhosis. The incidence of HCC was 2.1 per 100 person‐years (95% CI, 1.9–2.4) among patients with cirrhosis and 0.5 per 100 person‐years (95% CI, 0.3–0.7) among patients with F3 fibrosis. In a meta‐regression analysis among patients with cirrhosis, older age (adjusted rate ratio [aRR] per 10‐year increase in mean/median age, 1.32; 95% CI, 1.00–1.73) and prior decompensation (aRR per 10% increase in the proportion of patients with prior decompensation, 1.06; 95% CI, 1.01–1.12) were associated with an increased incidence of HCC. Longer follow‐up after HCV cure was associated with a decreased incidence of HCC (aRR per year increase in mean/median follow‐up, 0.87; 95% CI, 0.79–0.96). Conclusions Among patients with cirrhosis, the incidence of HCC decreases over time after HCV cure and is lowest in patients with younger age and compensated cirrhosis. The substantially lower incidence in F3 fibrosis is below the recommended threshold for cost‐effective screening. The results should encourage the development of validated predictive models that better identify at‐risk individuals, especially among patients with F3 fibrosis.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta‐analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

The Cyclophilin Inhibitor Rencofilstat Decreases HCV-induced Hepatocellular Carcinoma Independently of Its Antiviral Activity

Stauffer,

Bobardt,

Ure

et al. 2023

Preprint

View full text Add to dashboard Cite

There is an urgent need for the identification of new drugs that inhibit HCV-induced hepatocellular carcinoma (HCC). Our work demonstrates that cyclophilin inhibitors (CypI) represent such new drugs. We demonstrated that the non-immunosuppressive cyclosporine A (CsA) analog (CsAa) rencofilstat possesses dual therapeutic activities for the treatment of HCV infection and HCV-induced HCC. Specifically, we showed that HCV infection of humanized mice results in the progressive development of HCC. This was true for four genotypes tested (1 to 4). Remarkably, we demonstrated that rencofilstat inhibits the development of HCV-induced HCC in mice even when added 16 weeks post-infection when HCC is well established. Importantly, we showed that rencofilstat drastically reduces HCC progression independently of its anti-HCV activity. Indeed, the CypI rencofilstat inhibits HCC while other anti-HCV agents such as NS5A (NS5Ai) and NS5B (NS5Bi) fail to reduce HCC. In conclusion, this study shows for the first time that the CypI rencofilstat represents a potent therapeutic agent for the treatment of HCV-induced HCC.

show abstract

Hepatocellular Carcinoma Incidence After Hepatitis C Cure Among Patients With Advanced Fibrosis or Cirrhosis: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

De novo hepatocellular carcinoma in patients with cirrhosis due hepatitis C virus infection after treatment with direct antiviral agents

Cited by 4 publications

References 0 publications

HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta‐analysis

HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta‐analysis

The Cyclophilin Inhibitor Rencofilstat Decreases HCV-induced Hepatocellular Carcinoma Independently of Its Antiviral Activity

Hepatocellular Carcinoma Incidence After Hepatitis C Cure Among Patients With Advanced Fibrosis or Cirrhosis: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About